secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001558370-25-008633
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure licenses ADC SIM0505 from Simcere Zaiming in deal worth up to $745M
----------------------------------------------------------------------------

- Upfront cash $12M + $5M payable upon financing or by Dec 31, 2025; milestones up to $745M plus tiered royalties up to double digits.
- Private placement: Simcere affiliate buys 4,063,633 shares at $0.492/share for $2M; registration rights granted.
- SIM0505 (CDH6-targeting ADC) in Phase 1 in China; US Phase 1 expected Q3 2025 with initial data in H1 2026.
- NextCure also obtains non-exclusive license to Simcere's linker/payload for a novel target ADC; Simcere retains Greater China rights.
- Cash runway into mid-2026 based on current resources; company expects to exhaust sooner if assumptions prove incorrect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025008633/0001558370-25-008633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025008633/nxtc-20250613x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer